US 10675303
Extracellular matrix compositions for the treatment of cancer
granted A61KA61K31/282A61K33/243
Quick answer
US patent 10675303 (Extracellular matrix compositions for the treatment of cancer) held by Adaptive Biologix, Inc. expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Adaptive Biologix, Inc.
- Grant date
- Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/282, A61K33/243, A61K35/12, A61K35/13